Surrogates under scrutiny: Fallible correlations, fatal consequences

BMJ (Online)

Volumn 343, Issue 7820, 2011, Pages

  Moynihan, Ray ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; VIRUS RNA;

BLOOD PRESSURE; BONE DENSITY; DISEASE MARKER; DRUG MEGADOSE; DRUG QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; REVIEW; RISK REDUCTION; STROKE; TUMOR VOLUME;

BIOLOGICAL MARKERS; HEALTH STATUS; HUMANS; PREVENTIVE MEDICINE; RISK ASSESSMENT; SAMPLE SIZE;

EID: 84859003632     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5160     Document Type: Review

References (25)

1. Greene J. Prescribing by numbers; drugs and the definition of disease. Johns Hopkins University Press, 2007.
2. Moynihan R. A new deal on disease definition. BMJ 2011;342:d2548.
3. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412
4. Moore T. Deadly medicine. Simon and Shuster, 1995.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333
6. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
7. Micheel CM, Ball JR, eds. Institute of Medicine. Evaluation of biomarkers and surrogate endpoints in chronic disease. National Academies Press, 2010.
8. Taylor F., Ward K., Moore T.H.M., Burke M., Davey Smith G., Casas J.P., Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;1:CD004816.
9. Deckers J., Blumenthal R. Statins for primary prevention of cardiovascular disease. BMJ 2011;342:d1048.
10. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681
11. Do statins have a role in primary prevention? An update. Therapeutics Letter 2010;77. www.ti.ubc.ca/letter77.
12. NIH Consensus Development Conference Management of Hepatitis B, Final statement 2008. http://consensus.nih.gov/2008/hepb.htm.
13. De Laet C., Van Hout B., Burger H., Hofman A., Pols H. Bone density and risk of hip fracture in men and women: Cross sectional analysis. BMJ 1997;351:221-225 (Pubitemid 27326329)
14. Preventing Alzheimer's disease and cognitive decline, 2010. http://consensus.nih.gov/2010/alzstatement.htm.
15. ACCORD Study Group. Long term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
16. Yudkin J.S., Richter B., Gale E.A.M. Intensified glucose control in type 2 diabetes-whose agenda? Lancet 2010;377:1220-1222
17. Montori V., Isley W., Guyatt G. Waking up from the DREAM of preventing diabetes with drugs. BMJ 2007;334:882-884 (Pubitemid 46724329)
18. Shaughnessy A., Slawson D., Lewis Barnett B. What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. BMJ 2003;327:266.
19. Rose J. Industry influence in the creation of pay-for-performance quality measures. Qual Manage Health Care 2003;17: 27-34.
20. Heath I., Hippisley-Cox J., Smeeth L. Measuring performance and missing the point. BMJ 2007;335;1075-1076
21. NIH stops clinical trial on combination cholesterol treatment. NIH News 2011 May 26. www.nih.gov/news/health/may2011/nhlbi-26.htm.
22. Ioannidis J.P.A., Orestis A., Panagiotou M.D. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 2011;305:2200-2210
23. Bossuyt P. The thin line between hope and hype in biomarker research. JAMA 2011;305:2229-2230
24. Järvinen T., Sievänen H., Kannus P., Jokihaara J., Khan K. The true cost of pharmacological disease prevention. BMJ 2011;342:d2175.
25. Starfield B., Hyde J., Gervas J., Heath I. The concept of prevention: A good idea gone astray? J Epidemiol Community Health 2008;62:580-583 (Pubitemid 351960218)